Articles On Dimerix (ASX:DXB)

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights: ASX 200 trims early losses as sectors rebound Viva Energy under pressure after first-half update Lithium and uranium stocks show mixed reactions The ASX 200 began Tuesday’s session in the red, touching earl...

Prescient at critical stage of development with phase 2a trial underway for PTX-100 PTX-100 granted orphan drug and fast track designations by the US FDA, unlocking benefits Focus on advancing PTX-100 to potential registrational phase 2b t...

The S&P/ASX 200 Index (ASX: XJO) is having a positive start to the week. At the time of writing, the benchmark index is up 0.25% to 8,689.1 points. Four ASX shares that are rising more than most today are listed below. Here's why they a...

Highlights: Dimerix gains on milestone-rich licensing agreement Newmont lifts after delivering strong quarterly performance Titomic jumps following a successful capital raise As the broader S&P/ASX 200 index trades...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and on track to record a disappointing decline. At the time of writing, the benchmark index is down 0.5% to 8,664.4 points. Four ASX shares that are not letting that ho...

S&P/ASX 200 Index (ASX: XJO) gold stock Newmont Corp (ASX: NEM) is charging higher today. Newmont shares closed yesterday trading for $91.88. In morning trade on Friday, shares are changing hands for $96.01 apiece, up 4.5%. This sees Ne...

On Friday the 13th of December last year, Percheron Therapeutics (ASX:PER)  CEO Dr James Garner awaited the top-line results of the phase IIb Duchenne muscular dystrophy trial from his Brisbane lounge room. The company’s clinical developmen...

 Nanosonics has launched tweaked versions of its Trophon medical probe steriliser Amplia shares soar a further 36% on pancreatic cancer promise Dimerix looks to broaden its repertoire     Nanosonics (ASX:NAN) has launched updated iteratio...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

With the FDA’s blessing, Dimerix will use phase III trial endpoints that could lead to accelerated approval for its kidney disease drug Dimerix is confident of phase III success because an expert ‘peek’ at the blinded data shows it’s on th...

Tetratherix’s listed life starts on a solid note Dimerix pockets a $4.2 million milestone – with close to $1.4 billion to come Orthocell chalks up first commercial US procedure for its Remplir device Today’s ASX debut of wound management...

Botanix Pharmaceuticals (ASX:BOT) CEO Dr Howie McKibbon says investors shouldn’t rely just on management’s assertion that its anti-sweating drug Sofdra has – and we paraphrase – “the potential to be the world’s most successful dermatology d...

ASX pulls back from 0.55pc slide to dip 0.21pc Utilities leads recovery, up 0.74pc ASX All Ord Gold index climbs 0.62pc   ASX pulls out of tailspin to make up ground While the ASX closed lower today, down 0.21%, it was looking a lot worse...

Dimerix reports 200 adult patients now randomised and dosed in ACTION3 phase III trial in FSGS patients Number represents ~70% of adult patients to be dosed in the pivotal two-year trial Patients recruitment remains on track to complete do...

Highlights: ASX health sector eased, diverging from the broader ASX 200 gains during the week EMVision expanded its pivotal trial and welcomed Ramsay Health Care CEO to the board Dimerix launched clinical activities in Japan...

ASX health stocks dipped 0.82% over the past five days while the broader market has risen 1.26% EMVision appoints Ramsay Health Care CEO to board and expands sites of pivotal trial First Japan site opens for Dimerix’s phase III clinical tr...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

First site in Japan opens for Dimerix’s ACTION3 phase III clinical trial of DMX-200 in rare kidney disease Opening of trial site triggers first development milestone payment of ¥400 million (~A$4.3m) to Dimerix Further sites forecast to op...

The ASX 200 is looking to end Week 22 on a downward tilt, with endless Trump tariff changes likely to push the Aussie bourse towards a mildly red close. Listen to the HotCopper podcast for in-depth discussions and insights on all the big...

Dimerix (ASX:DXB) has kicked off a key trial in Japan (in terms of patient recruitment) seeking to treat inflammatory diseases. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throu...

AI is reshaping microbiology in the labs Big Pharma taps Clever Culture’s APAS system Here are ASX biotechs with global health deals    Step into a modern microbiology lab today and you might notice something’s different. The culture plat...

ASX slides 0.45pc, falling from new 50-day high Gold and resources stocks temper losses Info Tech sector leads market down   After a month of almost uninterrupted gains, the ASX has taken a dip today, shedding 0.45%. The combination of Mo...

AFT Pharmaceuticals boosts revenue, but profits still lag Telix Pharmaceuticals chair and CEO reflect on a prosperous 2024 – and promise more riches to come Dimerix’s pivotal trail passes another safety check   The bourse’s ‘forgotten’ dr...

Australia has become well-known for its paediatric drug discovery with several life-altering treatments CSL is a global leader in developing therapies for children with haemophilia and other serious blood disorders Neurotech International...

As a former bus driver, Dimerix (ASX:DXB) CEO Dr Nina Webster knows that the drug development journey is just as important as the destination when it comes to delivering value to shareholders. The therapeutic trip can be painfully long, esp...

With the gold price hovering near all-time highs, should you buy S&P/ASX 200 Index (ASX: XJO) gold stocks or gold exchange-traded funds (ETFs)? We'll dig into that million-dollar question below. But first… What's been sending the gold...

Highlights Dimerix (DMX) leads the gains on renewed attention around pharmaceutical developments Tempest Minerals (TEM) climbs following resource news related to the Remorse iron deposit Dreadnought Resources (DRE) declines...

Boss Energy Ltd (ASX: BOE) shares have enjoyed a tremendous run over the past month. How tremendous? Well, on 7 April, the S&P/ASX 200 Index (ASX: XJO) uranium stock closed the day trading for $2.10. At market close yesterday, those sa...

Highlights: Dimerix Limited has quoted additional ordinary securities on the ASX. The development follows conversion of previous instruments into tradeable shares. ASX:DXB remains focused on advancing kidney disease treatmen...

The NextDC Ltd (ASX: NXT) share price has surged over the last couple of weeks, gaining about 30%. The data centre operator's share price added to its run on Tuesday, rising around 8% with some positive news coming out of the company....

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

If you are on the hunt for some new ASX 200 stocks to buy, then it could be worth listening to what Goldman Sachs is saying about the two listed below. They have both been named on its highly coveted Asia-Pacific conviction list in May, whi...

The S&P/ASX 200 Index (ASX: XJO) endured another negative trading day this Tuesday, building on the losses we saw kick off the trading week yesterday. By the time the markets shut, the ASX 200 had...

The S&P/ASX 200 Index (ASX: XJO) is having a subdued session on Tuesday. In afternoon trade, the benchmark index is down slightly to 8,156.1 points. Four ASX shares that are falling more than most today are listed below. Here's why the...

Dimerix receives upfront payment of US$30 million for US licensing deal of DMX-200 Company eligible for further potential development milestones of up to US$560 million plus tiered royalties Fourth license deal executed for phase III clini...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is no course to record a small decline. At the time of writing, the benchmark index is down almost 0.2% to 8,144.3 points. Four ASX shares that are not letting that hold them back are...

By now, you've probably read a million articles about Warren Buffett stepping down. Yes, the great man has hit the headlines again. No, this won't be one of those articles. This one is about chocolate, and it ends with two ASX stocks you mi...

The NextDC Ltd (ASX: NXT) share price is charging higher today. Shares in the S&P/ASX 200 Index (ASX: XJO) data centre operator and developer closed yesterday trading for $12.66. In morning trade on Tuesday, shares are changing hands fo...

The US health sector shows signs of stabilising as chaos subsides Immutep will meet with the FDA following “excellent” follow-on trial results When it comes to its sagging share price, Immuron leaves blame-shifting to the defeated Liberals...

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

It was a big week for our biotech Investment Dimerix (ASX: DXB). Up 50% on huge volumes from news of a US licensing deal that could be worth up to $1BN. DXB is up nearly 1,000% since its 8 cent cap raise in May 2023. What does it actuall...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a strong finish this Friday in what has been a strong week for the share market. By the time the closing bell rang, the ASX 200 had jumped up a healthy 1.13...

Highlights: Dateline Resources’ share price surged after political attention on rare earth minerals. Peninsula Energy experiences leadership changes amid halted trading and a downgrade. Biotech companies Telix and Dimerix fa...

Around this time every year, we start to hear a certain saying being muttered around the proverbial ASX investing water coolers. That phrase is 'sell in May and go away'. You might have also heard the antiquated long form of this proverb, w...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.9% to 8,218.5 points. Four ASX shares that are rising more than most today are listed below. Here's w...

Can you believe it has only been one month since US President Donald Trump stood in the Rose Garden of the White House and announced those sweeping and savage 'reciprocal tariffs' that upended global markets? In many ways, it feels like an...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin US markets racheted up another rally, making it eight consecutive positive days. Aft...

The ASX200 closed up 0.24% at 8,145 points. The IT sector surged and was the best performer, up 4%, followed by Real Estate, up 1.6%, and Staples, up 1.4%. Energy shed some of yesterday’s gains and finished down, 1.35%, followed by Ma...